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EDITORIAL
Is angiotensin II’s role in fibrosis as easy as PAI(-1)?
It is now well recognized that there is a strong thera- gesting its possible role in fibrogenesis. Its specific role
peutic value in inhibition of the renin-angiotensin system in the progression of renal disease is difficult to deter-
(RAS) in delaying the progression of chronic renal dis- mine since it is generally expressed in conditions associ-
ease. Particular interest is piqued by the observation that ated with the enhanced expression of multiple pro-
inhibition of the RAS is associated with better outcomes fibrotic signals. There are no specific inhibitors for PAI-1
in groups of patients who are not generally considered and studies aimed at determining fibrogenic responses
hypertensive [1]. The data are compelling insofar as they in PAI-1 null mice have yet to be published.
suggest that local angiotensin II type 1 (AT1)-receptor Angiotensin II treatment of renal cells in vitro results
mediated activity may contribute to the process of renal in increased production of PAI-1 [3], suggesting that pro-
fibrosis in a fashion independent of its effects on blood fibrotic effects of Ang II are mediated, at least in part,
pressure. The idea is further supported by two lines of via direct activation of PAI-1 synthesis. Because of the
experimental evidence: (1) The use of angiotensin-con- potentially important contribution that PAI-1 activity
verting enzymes (ACE) inhibitors or AT1 antagonists might exert on ECM homeostasis, it is of interest to
ameliorates renal fibrosis and attenuates expression of dissect out the molecular mechanisms by which Ang II
extracellular matrix-related genes in several models of activity results in altered expression of the PAI-1 gene.
kidney disease, including those not associated with hy- In this issue of Kidney International, Nakamura et al
pertension; and (2) angiotensin II (Ang II) administra- publish a report that takes initial steps toward addressing
tion to a number of different cells in vitro enhances the these issues [6]. Acute infusions of Ang II to rats resulted
production of extracellular matrix proteins [2, 3]. in profound increases in both mean arterial pressure
Still, controversy exists with regard to the role that (MAP) and the mRNA expression of PAI-1 in kidney
hemodynamic factors might play in the genesis of the as well as aorta, heart and liver. The administration of
fibrotic response. Clinically speaking, while many studies a specific AT1-receptor antagonist completely blocked
demonstrate the added renoprotective advantage of both the increase in MAP and the elevation in PAI-1
RAS inhibition versus other means of blood pressure mRNA. Interestingly, a dose of hydralazine sufficient to
control, it remains apparent that in some groups of pa- block the Ang II-mediated rise in MAP did not inhibit
tients, any means of achieving a desired target blood the enhanced expression of PAI-1 mRNA. Thus, this
pressure is crucial [4]. Experimentally, one cannot ignore study clearly demonstrates an important observation:
the fact that animal models of hypertension exist that that AT1 receptor-mediated activity can increase PAI-1
are characterized by low renin levels. Kidneys from these synthesis independent of blood pressure effects.
animals demonstrate fibrosis and express many of the Despite these important observations, it would be
same profibrotic genes activated by Ang II in vitro [2]. imprudent to dismiss the importance of AT1 receptor-
Thus, it is clear that blood pressure effects most certainly induced alterations in hemodynamic activity in regulat-
influence the profibrotic milieu in the kidney [2]. ing profibrotic molecules such as PAI-1. Indeed, further
In an effort to determine the mechanism by which investigation using alternative experimental paradigms
renal fibrosis is enhanced by the RAS, investigators have might demonstrate interesting results. The administra-
begun to study the expression of molecules whose activ- tion of Ang II was via a four hour IV infusion at a dose
ity directly affects extracellular matrix (ECM) homeosta- of 600 ng/kg/min. The dose was selected on the basis of
sis. One such molecule is plasminogen activator inhibi- its ability to maximally stimulate the expression of PAI-1
tor-1 (PAI-1), a potent inhibitor of both the tissue-type mRNA in this setting [6]. However, this dose of Ang II
and urokinase-type plasminogen activators [5]. PAI-1 is 20- to 100-fold higher than that required to significantly
suppresses fibrinolytic activity and therefore may be im- raise MAP in rats. On the basis of this design, the reader
portant in tissue remodeling following injury [5]. PAI-1 should be cognizant of at least two important issues: (1)
has been identified at sites of active renal disease, sug- Both blood pressure and direct receptor activity might
contribute additively or synergistically toward the ex-
pression of PAI-1 mRNA. One might reasonably con-Key words: chronic renal disease, renin-angiotensin system, hemody-
namics, blood pressure control. sider that the threshold dose of Ang II on the PAI-1
expression can be affected by the blood pressure compo-Ó 2000 by the International Society of Nephrology
460
Editorial 461
nent. Therefore, rather than using doses that give maxi- that the RAS influences fibrosis by participating in the
synthesis many different pro-fibrotic molecules that aremum responses, it would be more appropriate to gener-
ate dose-response curves in the presence or absence of also controlled by multiple factors such as shear stress,
hypoxia, glucose levels and inflammatory factors. Re-blood pressure control in an effort to determine the
relative contribution of each component. gardless of the mechanism, the nephrologist should be
grateful that well-established therapeutic agents exist(2) Chronic (14 days) infusion of Ang II at similarly
high doses results in sustained pressor activity and evi- whose clinical characteristics are well-known and whose
potential benefits in treating renal diseases of diversedence of renal glomerular, vascular and tubulointerstitial
damage [7]. Lower doses that produce more modest pres- etiologies are becoming increasingly apparent.
sor responses are not clearly fibrogenic. However, chronic
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